Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea
· Delayed Price · Currency is KRW 3,380.00
-65.00 (-1.89%)
At close: Jun 27, 2025, 3:30 PM KST
Seoul Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 53,037 | 53,580 | 52,459 | 50,057 | 40,463 | 52,232 | Upgrade
|
| Other Revenue | -0 | - | - | - | - | - | Upgrade
|
| Revenue | 53,037 | 53,580 | 52,459 | 50,057 | 40,463 | 52,232 | Upgrade
|
| Revenue Growth (YoY) | -0.59% | 2.14% | 4.80% | 23.71% | -22.53% | -3.19% | Upgrade
|
| Cost of Revenue | 20,648 | 20,651 | 20,871 | 17,910 | 14,980 | 17,004 | Upgrade
|
| Gross Profit | 32,389 | 32,929 | 31,588 | 32,146 | 25,483 | 35,228 | Upgrade
|
| Selling, General & Admin | 28,220 | 27,973 | 26,710 | 27,154 | 24,805 | 26,424 | Upgrade
|
| Research & Development | 2,620 | 2,620 | 3,141 | 3,263 | 6,367 | 2,732 | Upgrade
|
| Operating Expenses | 31,648 | 31,401 | 30,375 | 30,408 | 31,197 | 29,117 | Upgrade
|
| Operating Income | 740.64 | 1,528 | 1,213 | 1,739 | -5,713 | 6,111 | Upgrade
|
| Interest Expense | -442.12 | -442.12 | -442.51 | -1,124 | -1,132 | -1,239 | Upgrade
|
| Interest & Investment Income | 301.9 | 301.9 | 383.64 | 325.22 | 122.1 | 313.24 | Upgrade
|
| Currency Exchange Gain (Loss) | 256.31 | 256.31 | 15.32 | 72.17 | 87.73 | -61.66 | Upgrade
|
| Other Non Operating Income (Expenses) | -13.28 | 49.15 | 2,819 | 45.18 | -2,760 | -1,764 | Upgrade
|
| EBT Excluding Unusual Items | 843.45 | 1,693 | 3,988 | 1,057 | -9,396 | 3,360 | Upgrade
|
| Gain (Loss) on Sale of Investments | 67.49 | 67.49 | 63.71 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.05 | -0.05 | -8.26 | -0.02 | 2.19 | 2.54 | Upgrade
|
| Asset Writedown | - | - | - | -2,177 | -198.8 | -4,369 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -167.31 | Upgrade
|
| Pretax Income | 910.88 | 1,760 | 4,044 | -1,120 | -9,592 | -1,174 | Upgrade
|
| Income Tax Expense | -30.79 | 61.86 | 526.39 | -1,975 | 96.14 | 167.53 | Upgrade
|
| Net Income | 941.67 | 1,699 | 3,517 | 855.09 | -9,689 | -1,342 | Upgrade
|
| Net Income to Common | 941.67 | 1,699 | 3,517 | 855.09 | -9,689 | -1,342 | Upgrade
|
| Net Income Growth | 50.42% | -51.71% | 311.34% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 12 | 9 | 9 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 12 | 9 | 9 | 8 | Upgrade
|
| Shares Change (YoY) | - | - | 29.84% | 5.34% | 0.31% | 0.15% | Upgrade
|
| EPS (Basic) | 80.77 | 145.69 | 301.68 | 95.23 | -1136.55 | -157.86 | Upgrade
|
| EPS (Diluted) | 80.77 | 145.69 | 301.68 | 95.23 | -1136.55 | -157.86 | Upgrade
|
| EPS Growth | 50.42% | -51.71% | 216.80% | - | - | - | Upgrade
|
| Free Cash Flow | -7,219 | -5,237 | 3,372 | -1,311 | -2,831 | 5,285 | Upgrade
|
| Free Cash Flow Per Share | -619.16 | -449.20 | 289.20 | -146.00 | -332.16 | 621.86 | Upgrade
|
| Gross Margin | 61.07% | 61.46% | 60.21% | 64.22% | 62.98% | 67.45% | Upgrade
|
| Operating Margin | 1.40% | 2.85% | 2.31% | 3.47% | -14.12% | 11.70% | Upgrade
|
| Profit Margin | 1.78% | 3.17% | 6.71% | 1.71% | -23.95% | -2.57% | Upgrade
|
| Free Cash Flow Margin | -13.61% | -9.78% | 6.43% | -2.62% | -7.00% | 10.12% | Upgrade
|
| EBITDA | 3,360 | 4,017 | 3,141 | 4,352 | -3,185 | 8,555 | Upgrade
|
| EBITDA Margin | 6.33% | 7.50% | 5.99% | 8.69% | -7.87% | 16.38% | Upgrade
|
| D&A For EBITDA | 2,619 | 2,490 | 1,928 | 2,613 | 2,528 | 2,443 | Upgrade
|
| EBIT | 740.64 | 1,528 | 1,213 | 1,739 | -5,713 | 6,111 | Upgrade
|
| EBIT Margin | 1.40% | 2.85% | 2.31% | 3.47% | -14.12% | 11.70% | Upgrade
|
| Effective Tax Rate | - | 3.51% | 13.02% | - | - | - | Upgrade
|
| Advertising Expenses | - | 244.7 | 282.26 | 340.07 | 306.66 | 237.1 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.